2024

1. A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)

   Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 821-833

2. Applicability of the Barcelona scale to assess the quality of cleanliness of mucosa at esophagogastroduodenoscopy

   Gastroenterologia y Hepatologia, Vol. 47, Núm. 3, pp. 246-252

3. Characterizing Hepatitis Delta in Spain and the gaps in its management

   Gastroenterologia y Hepatologia

4. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

   Therapeutic Advances in Gastroenterology, Vol. 17

5. Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study

   Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 727-733

6. Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study

   Gastroenterologia y Hepatologia

7. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

   Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

8. Contraceptive Recommendations for Women with Immune-Mediated Inflammatory Diseases: A Delphi Consensus

   Advances in Therapy, Vol. 41, Núm. 4, pp. 1372-1384

9. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

   Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 10, pp. 2062-2074.e11

10. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 17

11. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort

    Gastroenterologia y Hepatologia

12. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

13. HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.

    American Journal of Gastroenterology

14. Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 750-758

15. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

16. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

17. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

18. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

19. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

20. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853